September 06, 2011 / 17:00 IST
PINC Research has come out with its report on pharma space.
Alchemia investor briefing provides update on generic Arixtra:- Alchemia expects DRL to have 30-34% market share in generic Arixtra which was launched in July 2011.
- Post the launch of authorised generic, Alchemia will now share 50% of operating profit (from earlier 60%) as pricing discount would rise.
- Alchemia will reimburse certain (could be between USD5-9mn) amount of development expenses to DRL in next few months.
- Apicore and Reliable have filed DMF for generic Arixtra. Alchemia is confident that they will take at-least 2-3years to come to the market.
PINC Comments: Since 50% of the drug is sold through GPO and with authorised generic (Apotex) also launched, we don
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
